JimJimJimJim Posted June 24, 2013 Share Posted June 24, 2013 Jim Marshall (not a doctor) said ... Cabazitaxel after taxotere: men report improved quality of life, less pain and other prostate cancer symptoms. Another ASCO 2013 paper reported a PSA response rate of around 50% for cabazitaxel after taxotere. ... end Jim Quality of life (QoL) of patients with metastatic castration resistant prostate cancer (mCRPC) treated with cabazitaxel. This abstract is only available for 24 hours for members to get an email. After 24 hours the abstract will only be available through the link to the ASCO site below. CautionThis extract was published in association with the American Society of Clinical Oncology 2013 annual conference. Though the research behind it may have been excellent, your doctor cannot yet give much weight to it for a number of reasons, including: It is only an extract. The full paper may reveal information important for your treatment. The study has not yet had peer review - with doctors and researchers scrutinising the study closely for mistakes and limitations after it is published in a professional journal. Your doctor may already be aware of a limitations of the findings because of their wider reading. The link below is to a page or document that we do not control.Parts of it may be wrong or misleading.Check with your doctor if something interests you.If it is temporarily or permanently unavailable, you may receive an error message. Source URL: http://meetinglibrary.asco.org/content/113177-132 Link to comment Share on other sites More sharing options...
This topic is now archived and is closed to further replies.